{"nctId":"NCT00782340","briefTitle":"A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa","startDateStruct":{"date":"2008-09"},"conditions":["Symptomatic Neurogenic Orthostatic Hypotension (NOH)","Non-diabetic Neuropathy","Primary Autonomic Failure","Dopamine Beta Hydroxylase Deficiency"],"count":263,"armGroups":[{"label":"Droxidopa","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Droxidopa"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Droxidopa","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nTo be eligible for inclusion, each patient must fulfill the following criteria:\n\n* Male or female and aged 18 years or over\n* Clinical diagnosis of orthostatic hypotension associated with Primary Autonomic Failure (PD, MSA and PAF), Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Autonomic Neuropathies\n* A documented fall in systolic blood pressure of at least 20 mmHg, or in diastolic blood pressure of at least 10 mmHg, within 3 minutes after standing;\n* Provide written informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care.\n\nExclusion Criteria:\n\n* Currently taking ephedrine or midodrine\n* Patients taking ephedrine or midodrine must stop taking these drugs at least 2 days prior to their baseline visit (Visit 2).\n* The use of short-acting anti-hypertensive medications at bedtime is permitted.\n* Currently taking tri-cyclic antidepressant medication or other norepinephrine re-uptake inhibitors;\n* Have changed dose, frequency and or type of prescribed medication, within two weeks of study start (excluding ephedrine and midodrine)\n* History of more than moderate alcohol consumption\n* History of known or suspected drug or substance abuse\n* Women of childbearing potential who are not using a medically accepted contraception\n* For WOCP a serum beta HCG pregnancy test must be conducted at screening, and a urine pregnancy test must be conducted at baseline and study termination; the results must be negative at screening and at baseline for the patient to receive study medication.\n* Sexually active males whose partner is a WOCP and who do not agree to use condoms for the duration of the study and for 30 days after the last dose;\n* Women who are pregnant or breast feeding\n* Known or suspected hypersensitivity to the study medication or any of its ingredients\n* Pre-existing sustained severe hypertension (BP 180/110 mmHg in the sitting position)\n* Have atrial fibrillation or, in the investigator's opinion, have any other significant cardiac arrhythmia\n* Any other significant systemic, hepatic, cardiac or renal illness\n* Diabetes mellitus or insipidus\n* Have a history of closed angle glaucoma\n* Have a known or suspected malignancy\n* Have a serum creatinine level \\> 130 mmol/L\n* Patients with known gastrointestinal illness or other gastrointestinal disorder that may, in the investigator's opinion, affect the absorption of study drug\n* In the investigator's opinion, have clinically significant abnormalities on clinical examination or laboratory testing\n* In the investigator's opinion, are unable to adequately co-operate because of individual or family situation\n* In the investigator's opinion, are suffering from a mental disorder that interferes with the diagnosis and/or with the conduct of the study, e.g. schizophrenia, major depression, dementia\n* Are not able or willing to comply with the study requirements for the duration of the study\n* Have participated in another clinical trial with an investigational agent (including named patient or compassionate use protocol) within 4 weeks before the start of the study\n* Previous enrolment in the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Orthostatic Hypotension Questionnaire Score (OHQ)","description":"The OHQ is the average of two sub-scales, the Orthostatic Hypotension Symptom Assessment Scale (OHSA) and the Orthostatic Hypotension Daily Activities Scale (OHDAS). Each asks the patient to rate their symptoms or disease impact over the past week. The OHSA sub-scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. The OHDAS sub-scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.\n\nFor the change from randomization, negative numbers represent improvement from randomization in OHQ score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.83","spread":"2.067"},{"groupId":"OG001","value":"-0.93","spread":"1.691"}]}]}]},{"type":"SECONDARY","title":"Change in Ability to Conduct Activities of Daily Living Score (OHDAS Composite Score)","description":"OHDAS composite scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. A negative score indicates an improvement during the double-blind randomized phase relative to value at randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.98","spread":"2.310"},{"groupId":"OG001","value":"-0.92","spread":"1.816"}]}]}]},{"type":"SECONDARY","title":"Change in Orthostatic Hypotension Symptom Assessment (OHSA Composite) Score","description":"OHSA composite scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. A negative score indicates an improvement during the double-blind randomized phase relative to value at randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.68","spread":"2.125"},{"groupId":"OG001","value":"-0.95","spread":"1.901"}]}]}]},{"type":"SECONDARY","title":"Change in Activities Involving Standing a Short Time (OHDAS Item 1)","description":"OHDAS Item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. A negative score indicates an improvement during the double-blind randomized phase relative to value at randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"2.75"},{"groupId":"OG001","value":"-0.8","spread":"2.60"}]}]}]},{"type":"SECONDARY","title":"Change in Activities Involving Walking a Short Time (OHDAS Item 3)","description":"OHDAS Item 3 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. A negative score indicates an improvement during the double-blind randomized phase relative to value at randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"2.55"},{"groupId":"OG001","value":"-0.6","spread":"2.37"}]}]}]},{"type":"SECONDARY","title":"Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1)","description":"OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. A negative score indicates an improvement during the double-blind randomized phase relative to value at randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"3.20"},{"groupId":"OG001","value":"-1.1","spread":"2.58"}]}]}]},{"type":"SECONDARY","title":"Patient-Reported Clinical Global Improvement - Severity Scores","description":"The CGI-S is a 7 point scale ranging from a score of 1 (no symptoms) to 7 (severe symptoms). Patients were grouped according to OH severity at the end of the randomization period as follows;\n\nNormal-Borderline OH (CGI-S 1-2), Mild-Moderate OH (CGI-S 3-4), Marked OH-Most Ill with OH (CGI-S 5-7).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinician-Reported Clinical Global Improvement - Severity Scores","description":"The CGI-S is a 7 point scale ranging from a score of 1 (no symptoms) to 7 (severe symptoms). Patients were grouped according to OH severity at the end of the randomization period as follows;\n\nNormal-Borderline OH (CGI-S 1-2), Mild-Moderate OH (CGI-S 3-4), Marked OH-Most Ill with OH (CGI-S 5-7).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure (SBP) Measurements 3 Minutes Post Standing","description":"Change: standing systolic blood pressure at end of study minus standing systolic blood pressure at randomization. A positive score indicates an improvement during the double-blind randomized phase relative to value at randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":"22.89"},{"groupId":"OG001","value":"3.9","spread":"16.28"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":263},"commonTop":["Headache","Dizziness"]}}}